Gopten (Trandolapril)

Gopten (trandolapril) is indicated for several cardiovascular indications where reduction of blood pressure or cardiac workload is desired.

• Hypertension (high blood pressure) management, either as monotherapy or in combination with other antihypertensives.
• Chronic heart failure, to improve symptoms and reduce hospitalization risk.
• Post‑myocardial infarction therapy, as part of long‑term cardiovascular risk reduction.
• Diabetic nephropathy adjunct, when blood pressure control is needed to slow renal progression.
• Left ventricular dysfunction, as recommended by clinical guidelines.

The safety profile of trandolapril includes a range of observed adverse reactions, which are generally categorized by frequency and severity.

Common

• Cough, often dry and persistent.
• Dizziness or light‑headedness, especially after the first dose.
• Headache.
• Fatigue or mild weakness.

Serious

• Angioedema affecting the face, lips, tongue or airway.
• Severe hypotension leading to fainting or shock.
• Acute kidney injury manifested by rapid rise in serum creatinine.

Before initiating Gopten, clinicians should evaluate several patient‑specific factors to minimize risk and ensure appropriate use.

• Assess renal function; dose adjustment may be required in moderate to severe impairment.
• Monitor serum potassium and electrolytes, particularly when combined with potassium‑sparing diuretics or supplements.
• Review history of angioedema or hypersensitivity to ACE inhibitors.
• Use caution in patients with bilateral renal artery stenosis or severe aortic stenosis.
• Evaluate for pregnancy; ACE inhibitors are generally contraindicated during the second and third trimesters.
• Consider potential interactions with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect renal perfusion.

Trandolapril may interact with other medicines, altering its efficacy or increasing the likelihood of adverse effects.

Avoid

• Concomitant use with other ACE inhibitors, ARBs, or direct renin inhibitors due to additive risk of hyperkalaemia and renal dysfunction.
• Potassium supplements or potassium‑sparing diuretics, which can precipitate dangerous hyperkalaemia.
• Aliskiren in patients with diabetes or renal impairment, as this combination is contraindicated.

Use with caution

• NSAIDs, which may reduce antihypertensive effect and impair renal function.
• Diuretics, especially loop or thiazide types, which can increase the risk of hypotension and electrolyte imbalance.
• Lithium, as ACE inhibition may raise lithium concentrations and toxicity risk.